Trial Profile
A First in human clinical study of OraPro-COVID-19
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 01 Sep 2021
At a glance
- Drugs COVID-19 vaccine Stabilitech Biopharma (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- 30 Sep 2020 According to an iosBio media release, the company expect to initiate this trial in Q1 2021.
- 24 Mar 2020 New trial record
- 19 Mar 2020 According to a Stabilitech Biopharma media release, the company plans to initiate this study within weeks.
Most Recent Events
Trial Overview
Purpose
This trial will evaluate OraPro-COVID-19.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
Trial Details
Organisations
- Affiliations iosBio
Trial Dates
-
Initiation Dates
Planned : 01 Jan 2021
Other Details
- Design multicentre; prospective
- Phase of Trial Phase I
- Location Europe; USA
- Focus Adverse reactions; First in man
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| COVID-19 vaccine Stabilitech BiopharmaPrimary Drug | Oral |
-
|
OraPro-COVID-19
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 30 Sep 2020 | Other trial event | According to an iosBio media release, the Stabilitech Biopharma has changed its name to iosBio. Updated 01 Sep 2021 |
| 30 Sep 2020 | Other trial event | According to an iosBio media release, the company expect to initiate this trial in Q1 2021. Updated 01 Oct 2020 |
| 24 Mar 2020 | New trial record | New trial record Updated 24 Mar 2020 |
| 19 Mar 2020 | Other trial event | According to a Stabilitech Biopharma media release, the company plans to initiate this study within weeks. Updated 24 Mar 2020 |
References
-
Stabilitech Biopharma. Stabilitech's COVID-19 Vaccine Intended to Be Delivered in a Disruptive Thermally Stable Oral Capsule. Media-Rel 2020;.
Media Release -
Stabilitech Biopharma, iosBio. Stabilitech Biopharma announces name change to iosBio. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG